Enhancement of Ketone Supplements-Evoked Effect on Absence Epileptic Activity by Co-Administration of Uridine in Wistar Albino Glaxo Rijswijk Rats

Brunner, Brigitta

Rauch, Enikő

Ari, Csilla

D'Agostino, Dominic P

Kovács, Zsolt

2021

Both uridine and exogenous ketone supplements decreased the number of spike-wave discharges (SWDs) in a rat model of human absence epilepsy Wistar Albino Glaxo/Rijswijk (WAG/Rij) rats. It has been suggested that alleviating influence of both uridine and ketone supplements on absence epileptic activity may be modulated by A(1) type adenosine receptors (A(1)Rs). The first aim was to determine whether intraperitoneal (i.p.) administration of a specific A(1)R antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX; 0.2 mg/kg) and a selective adenosine A(2A) receptor antagonist (7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo [1,5-c]pyrimidine) (SCH 58261; 0.5 mg/kg) have a modulatory influence on i.p. 1000 mg/kg uridine-evoked effects on SWD number in WAG/Rij rats. The second aim was to assess efficacy of a sub-effective dose of uridine (i.p. 250 mg/kg) combined with beta-hydroxybutyrate salt + medium chain triglyceride (KSMCT; 2.5 g/kg, gavage) on absence epilepsy. DPCPX completely abolished the i.p. 1000 mg/kg uridine-evoked alleviating effect on SWD number whereas SCH 58261 was ineffective, confirming the A(1)R mechanism. Moreover, the sub-effective dose of uridine markedly enhanced the effect of KSMCT (2.5 g/kg, gavage) on absence epileptic activity. These results demonstrate the anti-epilepsy benefits of co-administrating uridine and exogenous ketone supplements as a means to treat absence epilepsy.

info:eu-repo/semantics/article

application/pdf

http://hdl.handle.net/10831/110803

doi:https://doi.org/10.3390/nu13010234

elte:000610666700001

elte:85100082433

elte:31840001

elte:1

elte:NUTRIENTS

elte:NUTRIENTS

elte:13

elte:33467454

elte:10089076

LOMS: https://edit.elte.hu/xmlui/bitstream/10831/110803/1/31840001.pdf

info:eu-repo/semantics/openAccess